Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10159569 | 0.91 | P2RY2 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16647475 | 0.89 | P2RY2 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9909477 | 0.88 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL93614 | 0.86 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4431691 | 0.85 | SLC29A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL18464384 | 0.85 | SLC29A1 (0.59) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL18536627 | 0.85 | SLC29A1 (0.59) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL20090522 | 0.85 | SLC29A1 (0.59) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL15197938 | 0.85 | SLC29A1 (0.59) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL23880678 | 0.84 | P2RY2 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728886-B | Lipid compounds and compositions containing carbonates for intracellular delivery of therapeutic agents | 摩登纳特斯有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-9278990-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150038451-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8871737-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| WO-2012040127-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | SLC28A1 59/4885SLC28A2 70/4885SLC29A1 32/4885 |
| US-20150038451-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | SLC28A1 59/4885SLC28A2 70/4885SLC29A1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.